← GE HealthCare overview

GE HealthCare vs Medtronic: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

GE HealthCare Technologies Inc. (GEHC)

Q3 2026
▲2▼2

GEHC Q3: Strong Orders and Deals Offset by CFO Exit and Recall

  • Record orders and backlog GE HealthCare beat Q2 estimates with 11% organic order growth and a record $23.9 billion backlog, signaling strong future revenue. A $500 million Catholic Health deal also boosted confidence.

    This shows robust demand and a healthy pipeline, a key positive driver for the stock.

  • New product approvals and dividend hike The company received European CE Mark for its photon-counting CT scanner and raised its dividend by 14%. It is also in advanced talks to buy Sofie Biosciences for about $1 billion.

    These events highlight innovation and shareholder returns, supporting the stock price.

  • CFO departure and fraud investigation The CFO left the company, and a securities-fraud investigation tied to the April Q1 earnings miss is ongoing. This raises concerns about management stability and financial reporting.

    Leadership turnover and legal issues can undermine investor trust and weigh on the stock.

  • Product recall and segment weakness A Class II recall of Centricity PACS software affected 1,443 systems due to wrong-patient data risk. Patient Care Solutions revenue fell 13.3%, and the stock is down 14.2% year to date.

    Recall and revenue decline are operational setbacks that pressure the stock price.

September 2026
▲3

GEHC's record orders, Europe CT clearance, $1B Sofie deal, dividend hike offset by software recall

  • Record $23.9B backlog on 11.1% order growth Q2 organic orders rose 11.1% with a record $23.9B backlog and 1.15x book-to-bill, and 85% of Q3 equipment revenue already secured. Strong future demand supports revenue visibility, though Patient Care Solutions revenue fell 13.3% with negative segment profit.

    This is the core demand signal that drives GEHC's revenue outlook and investor confidence.

  • Photonova Spectra CT gets CE Mark for Europe GEHC's photon-counting CT system won CE Mark, opening European sales in a market growing 29.4% a year. This expands the commercial opportunity for a high-end imaging product, though the stock slipped 1.1% after the news and remains down 14.2% year to date.

    New product approval expands GEHC's addressable market and future revenue potential.

  • Advanced talks to buy Sofie Biosciences for ~$1B GEHC is in advanced talks to acquire Sofie Biosciences for about $1 billion, adding radiopharmaceuticals and PET imaging agents. This would strengthen its pharmaceutical diagnostics business, though the deal could still fall apart and uses cash for growth.

    A major acquisition would expand GEHC's diagnostics pipeline and is a key strategic catalyst.

  • Dividend raised 14%, but Centricity PACS recall GEHC raised its quarterly dividend 14% to $0.04 and added a finance leader to its board, signaling confidence. But a voluntary Class II recall of Centricity PACS software across 1,443 systems over wrong-patient data risk could mean remediation costs and reputational damage.

    The dividend hike is a positive capital signal, while the recall is a real regulatory and operational counterweight.

Latest
▲3

GEHC's record orders, Europe CT clearance, $1B Sofie deal, dividend hike offset by software recall

  • Record $23.9B backlog on 11.1% order growth Q2 organic orders rose 11.1% with a record $23.9B backlog and 1.15x book-to-bill, and 85% of Q3 equipment revenue already secured. Strong future demand supports revenue visibility, though Patient Care Solutions revenue fell 13.3% with negative segment profit.

    This is the core demand signal that drives GEHC's revenue outlook and investor confidence.

  • Photonova Spectra CT gets CE Mark for Europe GEHC's photon-counting CT system won CE Mark, opening European sales in a market growing 29.4% a year. This expands the commercial opportunity for a high-end imaging product, though the stock slipped 1.1% after the news and remains down 14.2% year to date.

    New product approval expands GEHC's addressable market and future revenue potential.

  • Advanced talks to buy Sofie Biosciences for ~$1B GEHC is in advanced talks to acquire Sofie Biosciences for about $1 billion, adding radiopharmaceuticals and PET imaging agents. This would strengthen its pharmaceutical diagnostics business, though the deal could still fall apart and uses cash for growth.

    A major acquisition would expand GEHC's diagnostics pipeline and is a key strategic catalyst.

  • Dividend raised 14%, but Centricity PACS recall GEHC raised its quarterly dividend 14% to $0.04 and added a finance leader to its board, signaling confidence. But a voluntary Class II recall of Centricity PACS software across 1,443 systems over wrong-patient data risk could mean remediation costs and reputational damage.

    The dividend hike is a positive capital signal, while the recall is a real regulatory and operational counterweight.

July 2026
▲3▼1

GEHC beats Q2, wins $500M deal, but CFO exit and fraud probe weigh

  • Q2 beat and record backlog GEHC beat Q2 revenue and profit estimates, with organic orders up 11% and a record $23.9 billion backlog. This shows demand is strong and future sales are locked in, pushing the stock up as investors gain confidence in growth.

    The Q2 earnings beat is the main new event driving the stock this period.

  • $500M Catholic Health deal GEHC signed a 10-year, $500 million deal to supply over 1,300 machines and AI tools to Catholic Health. This adds a large, predictable revenue stream and shows its equipment is in demand, supporting the stock price.

    A major new contract that directly boosts future revenue and investor confidence.

  • CFO departure and fraud investigation CFO James Saccaro will step down on August 14, and a law firm is investigating possible securities fraud tied to the April Q1 earnings miss and guidance cut. These raise uncertainty about management and legal risks, which can weigh on the stock.

    New negative developments that create uncertainty and could pressure the stock.

  • Mayo Clinic theranostics study GEHC and Mayo Clinic launched a study using GEHC's StarGuide SPECT/CT to personalize prostate cancer treatment. This highlights its technology in a growing area, which can boost future sales and support the stock.

    A new collaboration that showcases GEHC's technology and potential for future growth.

▲3▼1

GEHC beats Q2, wins $500M deal, but CFO exit and fraud probe weigh

  • Q2 beat and record backlog GEHC beat Q2 revenue and profit estimates, with organic orders up 11% and a record $23.9 billion backlog. This shows demand is strong and future sales are locked in, pushing the stock up as investors gain confidence in growth.

    The Q2 earnings beat is the main new event driving the stock this period.

  • $500M Catholic Health deal GEHC signed a 10-year, $500 million deal to supply over 1,300 machines and AI tools to Catholic Health. This adds a large, predictable revenue stream and shows its equipment is in demand, supporting the stock price.

    A major new contract that directly boosts future revenue and investor confidence.

  • CFO departure and fraud investigation CFO James Saccaro will step down on August 14, and a law firm is investigating possible securities fraud tied to the April Q1 earnings miss and guidance cut. These raise uncertainty about management and legal risks, which can weigh on the stock.

    New negative developments that create uncertainty and could pressure the stock.

  • Mayo Clinic theranostics study GEHC and Mayo Clinic launched a study using GEHC's StarGuide SPECT/CT to personalize prostate cancer treatment. This highlights its technology in a growing area, which can boost future sales and support the stock.

    A new collaboration that showcases GEHC's technology and potential for future growth.

Q2 2026
▲3▼1

GEHC's AI product wins offset by weak profit guidance

  • Weak profit guidance drags stock GE HealthCare beat revenue expectations but missed full-year earnings guidance, sending shares down 11.1% to $60.91. Investors worry that costs or pricing pressure are eating into profits even as sales grow, which weighs on the stock.

    This is the biggest new event of the period and directly explains the stock's drop.

  • FDA clearance for AI radiation therapy tool GE HealthCare won FDA clearance for AI software that automates radiation therapy planning, making it faster and more personalized. This adds a new product to its oncology lineup and supports future revenue growth.

    A new regulatory approval expands the product portfolio and is a fresh positive catalyst.

  • RBC initiates with Outperform, stock jumps RBC started covering GE HealthCare with an Outperform rating, helping shares gain 5.08% even as broader markets fell. Analyst backing can boost investor confidence and attract new buyers.

    A new analyst rating is a fresh event that directly lifted the stock on the day.

  • AI imaging showcase and market growth GE HealthCare presented new AI imaging tools at medical conferences and the AI medical device market is projected to grow 27% yearly to $42 billion by 2030. Its $3 billion Caption Health deal positions it in this fast-growing area.

    Shows the company's long-term growth potential in AI, a key theme for future earnings.

June 2026
▲3▼1

GEHC's AI product wins offset by weak profit guidance

  • Weak profit guidance drags stock GE HealthCare beat revenue expectations but missed full-year earnings guidance, sending shares down 11.1% to $60.91. Investors worry that costs or pricing pressure are eating into profits even as sales grow, which weighs on the stock.

    This is the biggest new event of the period and directly explains the stock's drop.

  • FDA clearance for AI radiation therapy tool GE HealthCare won FDA clearance for AI software that automates radiation therapy planning, making it faster and more personalized. This adds a new product to its oncology lineup and supports future revenue growth.

    A new regulatory approval expands the product portfolio and is a fresh positive catalyst.

  • RBC initiates with Outperform, stock jumps RBC started covering GE HealthCare with an Outperform rating, helping shares gain 5.08% even as broader markets fell. Analyst backing can boost investor confidence and attract new buyers.

    A new analyst rating is a fresh event that directly lifted the stock on the day.

  • AI imaging showcase and market growth GE HealthCare presented new AI imaging tools at medical conferences and the AI medical device market is projected to grow 27% yearly to $42 billion by 2030. Its $3 billion Caption Health deal positions it in this fast-growing area.

    Shows the company's long-term growth potential in AI, a key theme for future earnings.

▲3▼1

GEHC's AI product wins offset by weak profit guidance

  • Weak profit guidance drags stock GE HealthCare beat revenue expectations but missed full-year earnings guidance, sending shares down 11.1% to $60.91. Investors worry that costs or pricing pressure are eating into profits even as sales grow, which weighs on the stock.

    This is the biggest new event of the period and directly explains the stock's drop.

  • FDA clearance for AI radiation therapy tool GE HealthCare won FDA clearance for AI software that automates radiation therapy planning, making it faster and more personalized. This adds a new product to its oncology lineup and supports future revenue growth.

    A new regulatory approval expands the product portfolio and is a fresh positive catalyst.

  • RBC initiates with Outperform, stock jumps RBC started covering GE HealthCare with an Outperform rating, helping shares gain 5.08% even as broader markets fell. Analyst backing can boost investor confidence and attract new buyers.

    A new analyst rating is a fresh event that directly lifted the stock on the day.

  • AI imaging showcase and market growth GE HealthCare presented new AI imaging tools at medical conferences and the AI medical device market is projected to grow 27% yearly to $42 billion by 2030. Its $3 billion Caption Health deal positions it in this fast-growing area.

    Shows the company's long-term growth potential in AI, a key theme for future earnings.

Medtronic PLC (MDT)

Q3 2026
▲6▼3

Medtronic gains on reimbursement, acquisitions, AI launches; risks persist

  • Renal denervation reimbursement win Medtronic secured permanent reimbursement codes for its renal denervation therapy, a key step to commercial adoption. This should drive sales growth and strengthen its position in hypertension treatment.

    This is a new regulatory and commercial milestone that directly supports future revenue.

  • SPR Therapeutics acquisition completed Medtronic completed the acquisition of SPR Therapeutics, adding a peripheral nerve stimulation platform. This expands its pain management portfolio and offers a new growth avenue.

    This is a new acquisition that broadens Medtronic's product offerings and potential revenue.

  • AI-native surgical platform launched Medtronic launched an AI-native surgical platform with FDA clearance, aiming to enhance surgical outcomes. This innovation could differentiate its offerings and drive adoption.

    This is a new product launch that showcases Medtronic's technological advancement.

  • LigaSure cleared for Hugo robot FDA clearance for LigaSure on the Hugo robot expands the robot's capabilities. This strengthens Medtronic's competitive position in robotic surgery against Intuitive Surgical.

    This is a new regulatory clearance that enhances the Hugo robot's functionality.

  • UBS upgrade and strong revenue growth UBS upgraded Medtronic stock, citing improving fundamentals. Revenue grew 8.4%, a decade high, and guidance was raised, reflecting strong business momentum.

    This is a new analyst upgrade and financial performance update that boosts investor confidence.

  • MiniMed diabetes spin-off advances Medtronic advanced the spin-off of its MiniMed diabetes business, a strategic move to unlock value. This could streamline operations and focus on core medtech.

    This is a new corporate action that may enhance shareholder value.

  • Octopus 4 recall and Bravo CF alert A Class II recall for Octopus 4 devices and an FDA alert linking 184 injuries to Bravo CF devices raise safety concerns. These may lead to regulatory scrutiny and reputational damage.

    These are new negative regulatory events that could impact sales and trust.

  • Hernia mesh verdict and lawsuits An $88 million hernia mesh verdict and over 2,400 pending lawsuits create legal overhang. This poses financial risk and distracts management.

    This is a new legal development with potential financial impact.

  • Tariffs and competitive pressures Medtronic faces $250 million in annual tariffs and competitive pressure from Abbott and J&J. Physician caution in cardiovascular procedures adds uncertainty.

    These are ongoing external challenges that could weigh on margins and growth.

August 2026
▲2▼2

Medtronic gains on strong earnings, upgrade, and pipeline expansion

  • UBS upgrade and decade-high revenue growth UBS upgraded Medtronic to Buy, and revenue grew 8.4%, the fastest in a decade, driven by an 88% jump in Cardiac Ablation Solutions. Q1 beat estimates, leading to raised full-year guidance.

    This point captures the main positive drivers that boosted investor confidence and the stock price.

  • Pipeline expansion through acquisitions and partnerships Medtronic expanded its pipeline with acquisitions, a $700 million robotics partnership, and approvals for the Affera system, strengthening its position in key markets and supporting future growth.

    This point highlights strategic moves that contribute to long-term growth potential.

  • Tariffs, legal verdict, and FDA alert create headwinds Medtronic faces $250 million in annual tariffs, an $88 million hernia mesh verdict with over 2,400 lawsuits pending, and an FDA alert linking 184 injuries to Bravo CF devices, adding legal and cost pressures.

    This point outlines the significant risks that could weigh on the stock and investor sentiment.

  • Competitive pressure and physician caution Competition from Abbott and Johnson & Johnson, along with physician caution in cardiovascular procedures, poses ongoing challenges that could limit Medtronic's market share and growth.

    This point addresses external competitive and behavioral factors that may hinder performance.

Latest
▲3

Medtronic Beats, Raises Guidance, Expands Robotics and Ablation

  • Q1 beat and raised guidance Medtronic reported 13.7% revenue growth to $9.76 billion and raised full-year guidance, with adjusted EPS up 15.1%. An extra week added $570 million, so growth won't repeat at that pace, but the beat and higher outlook support the stock.

    This is the biggest new financial event, directly driving investor confidence and the stock's valuation.

  • Cardiac Ablation Solutions tops $2B Medtronic's Cardiac Ablation Solutions unit surpassed $2 billion in trailing 12-month revenue, ahead of its target, helped by new approvals for the Affera system in Europe and Canada. This shows its bet on heart-rhythm devices is paying off.

    It highlights a key growth driver and validates Medtronic's competitive position in a fast-growing market.

  • $700M robotics deal expands offerings Medtronic signed a $700 million partnership with Cornerstone Robotics to distribute the Sentire surgical system globally, adding a second robotics platform alongside its Hugo system. This broadens its menu for hospitals and could boost procedure volumes over time.

    It is a major new strategic investment that expands Medtronic's robotics presence and future revenue potential.

  • Legal and regulatory setbacks Medtronic faced an $88 million hernia mesh verdict and an FDA early alert for its Bravo CF delivery devices after 184 injuries. These are negative for sentiment and could lead to costs, but they are smaller than the positive growth drivers.

    It provides a fair counterweight, showing real risks that could pressure the stock despite strong results.

September 2026
▲3

Medtronic's strong quarter and new diabetes spin-off drive analyst optimism

  • FDA clears LigaSure for Hugo robotic surgery system Medtronic won FDA clearance to use its LigaSure vessel-sealing device on the Hugo robotic surgery system in the U.S. This makes Hugo more attractive to hospitals and helps Medtronic compete with Intuitive Surgical and Johnson & Johnson, supporting future sales growth.

    New regulatory approval expands the Hugo ecosystem and addresses competition in robotic surgery.

  • Medtronic launches exchange offer to spin off MiniMed diabetes unit Medtronic launched an exchange offer to split off at least 80.1% of its MiniMed diabetes business, offering shareholders a 7% discount. This simplifies the company and could unlock value, though the diabetes unit's future performance remains uncertain.

    New corporate action that could reshape Medtronic's business and investor perception.

  • Analyst price-target hikes follow Q1 beat, but ratings split After Medtronic's strong Q1 results, analysts raised price targets, with some seeing more upside and others staying neutral. Hedge funds increased stakes and short interest fell, suggesting growing confidence, but the debate over a re-rating continues.

    New analyst actions and positioning data show market reaction to the quarter and future outlook.

▲3

Medtronic's strong quarter and new diabetes spin-off drive analyst optimism

  • FDA clears LigaSure for Hugo robotic surgery system Medtronic won FDA clearance to use its LigaSure vessel-sealing device on the Hugo robotic surgery system in the U.S. This makes Hugo more attractive to hospitals and helps Medtronic compete with Intuitive Surgical and Johnson & Johnson, supporting future sales growth.

    New regulatory approval expands the Hugo ecosystem and addresses competition in robotic surgery.

  • Medtronic launches exchange offer to spin off MiniMed diabetes unit Medtronic launched an exchange offer to split off at least 80.1% of its MiniMed diabetes business, offering shareholders a 7% discount. This simplifies the company and could unlock value, though the diabetes unit's future performance remains uncertain.

    New corporate action that could reshape Medtronic's business and investor perception.

  • Analyst price-target hikes follow Q1 beat, but ratings split After Medtronic's strong Q1 results, analysts raised price targets, with some seeing more upside and others staying neutral. Hedge funds increased stakes and short interest fell, suggesting growing confidence, but the debate over a re-rating continues.

    New analyst actions and positioning data show market reaction to the quarter and future outlook.

▲3▼1

Medtronic beats Q1, raises guidance on heart device strength

  • Q1 beat and raised guidance Medtronic reported fiscal Q1 revenue of $9.8 billion, up 13.7%, and adjusted EPS of $1.45, beating estimates. It raised full-year organic growth guidance to 7.25%-7.75% and EPS to $5.94-$6.00. This shows the business is growing faster than expected, which lifts the stock.

    This is the main new event that directly moves MDT's price.

  • Cardiac Ablation Solutions surge Cardiac Ablation Solutions grew 88% worldwide, and Cardiac Rhythm Management rose 15%. These heart-related products are driving most of the growth. Continued strength here supports the stock because it shows Medtronic is winning in a key market.

    It explains the underlying driver of the strong quarter and future growth.

  • Strategic deals and partnerships Medtronic completed acquisitions of Scientia Vascular and SPR Therapeutics, announced a partnership with Cornerstone Robotics, and invested in Pi-Cardia. These moves expand its product pipeline and technology, which can support future growth and investor confidence.

    New deals signal long-term growth potential beyond the current quarter.

  • Tariff costs and competition Medtronic expects $250 million in annual tariff costs, with $75 million hitting Q1. Also, Abbott's new diabetes device adds competition. These are real headwinds that could pressure profits and limit upside, even as the core business grows.

    It provides a fair counterweight to the positive earnings news.

▼3▲1

Medtronic's strong growth and UBS upgrade offset by tariff and legal headwinds

  • UBS upgrade and strong revenue growth UBS upgraded Medtronic to Buy, citing a turnaround. The company reported its highest annual revenue growth in a decade, with fiscal 2026 revenue up 8.4% to $36.4 billion, driven by a 78% surge in Cardiac Ablation Solutions. This positive momentum could attract more investors and push the stock higher.

    This is a new positive development that directly boosts investor confidence and the stock's outlook.

  • Tariff headwinds Medtronic absorbed a $74 million tariff impact in the latest quarter and expects roughly $250 million in fiscal 2027. These tariffs increase costs and could pressure profit margins, potentially weighing on the stock price.

    This is a new negative factor that affects future profitability and is a key concern for investors.

  • Hernia mesh lawsuit verdict A federal jury ordered Medtronic to pay $88 million in the first Covidien hernia mesh bellwether trial, with over 2,400 similar lawsuits pending. This creates legal uncertainty and potential financial liability, which could negatively impact the stock.

    This is a new legal development that introduces significant risk and could lead to further payouts.

  • Competitive pressure in cardiovascular Johnson & Johnson's MedTech cardiovascular segment grew only 3.1%, and Abiomed declined 2% amid physician caution. This suggests a challenging environment for Medtronic's cardiovascular business, potentially limiting growth.

    This is a new competitive signal that highlights potential headwinds for Medtronic's cardiovascular sales.

July 2026
▲3▼1

Medtronic advances on reimbursement, AI surgery, and acquisitions

  • Permanent reimbursement codes proposed for renal denervation The AMA proposed permanent Category I codes for renal denervation, which would make it easier for hospitals to get paid for Medtronic's Symplicity Spyral blood-pressure treatment. That removes a big question mark over adoption, so more patients could get the therapy and Medtronic's sales could rise.

    This is a new regulatory catalyst that directly addresses a key overhang on Medtronic's RDN business.

  • Completes SPR Therapeutics acquisition for non-opioid pain care Medtronic finished buying SPR Therapeutics, adding a minimally invasive nerve-stimulation system to its pain portfolio. This expands its offerings in earlier-stage pain treatment and positions it as a more complete partner for pain clinics, potentially boosting future revenue.

    This is a new acquisition that expands Medtronic's pain therapy business and competitive position.

  • Unveils AI-native surgical platform and FDA-cleared AI app Medtronic launched Touch Surgery Aide, an AI computing platform for real-time surgical support, and received FDA clearance for Instrument Exit Point, its first real-time AI app for robotic surgery. This strengthens its Hugo robot ecosystem and could drive adoption and sales.

    This is a new product launch and regulatory clearance that enhances Medtronic's surgical robotics technology.

  • Class II recall of Octopus 4 devices Medtronic recalled 590 Octopus 4 Tissue Stabilizer devices due to an assembly issue. While the recall is small, it highlights quality-control challenges and could make some analysts more cautious about execution, potentially weighing on the stock.

    This is a new negative event that could affect investor sentiment on quality control.

▲3▼1

Medtronic advances on reimbursement, AI surgery, and acquisitions

  • Permanent reimbursement codes proposed for renal denervation The AMA proposed permanent Category I codes for renal denervation, which would make it easier for hospitals to get paid for Medtronic's Symplicity Spyral blood-pressure treatment. That removes a big question mark over adoption, so more patients could get the therapy and Medtronic's sales could rise.

    This is a new regulatory catalyst that directly addresses a key overhang on Medtronic's RDN business.

  • Completes SPR Therapeutics acquisition for non-opioid pain care Medtronic finished buying SPR Therapeutics, adding a minimally invasive nerve-stimulation system to its pain portfolio. This expands its offerings in earlier-stage pain treatment and positions it as a more complete partner for pain clinics, potentially boosting future revenue.

    This is a new acquisition that expands Medtronic's pain therapy business and competitive position.

  • Unveils AI-native surgical platform and FDA-cleared AI app Medtronic launched Touch Surgery Aide, an AI computing platform for real-time surgical support, and received FDA clearance for Instrument Exit Point, its first real-time AI app for robotic surgery. This strengthens its Hugo robot ecosystem and could drive adoption and sales.

    This is a new product launch and regulatory clearance that enhances Medtronic's surgical robotics technology.

  • Class II recall of Octopus 4 devices Medtronic recalled 590 Octopus 4 Tissue Stabilizer devices due to an assembly issue. While the recall is small, it highlights quality-control challenges and could make some analysts more cautious about execution, potentially weighing on the stock.

    This is a new negative event that could affect investor sentiment on quality control.

Q2 2026
▲2

Medtronic gains on rival stumbles, acquisitions, and AI push

  • Competitor weakness in electrophysiology Boston Scientific's 2026 guidance missed expectations, with its electrophysiology growth slowing. Analysts say Medtronic may be taking market share in that heart-rhythm device business, which would lift Medtronic's sales and support its stock price.

    Shows a real competitive win that can boost Medtronic's revenue and investor sentiment.

  • Completes $550 million Scientia Vascular acquisition Medtronic finished buying Scientia Vascular for $550 million, adding specialized guidewires and catheters for brain blood vessels. The deal slightly lowers earnings per share in fiscal 2027 but is expected to add to earnings after that, strengthening its neurovascular business.

    A concrete capital move that expands a key product line and has a clear, if delayed, financial benefit.

  • Tariff hit lowered but still a growing cost Medtronic's CEO cut the expected tariff cost for fiscal 2027 to $250 million from $300 million, thanks to supply-chain changes. But tariffs remain a real and rising expense, and new U.S. tariff threats could force another rethink. Strong growth in heart ablation and other units helps offset the pressure.

    Tariffs directly affect Medtronic's costs and profits, and the lowered estimate is a fresh update investors need to weigh.

  • Robotic surgery competition cuts both ways Jim Cramer warned that Intuitive Surgical now faces real competition from Medtronic's Hugo robot, which is positive for Medtronic. But a separate report says Intuitive's dominant position is getting stronger, with most surgeons trained on its system and hospitals reluctant to switch, making Hugo an alternative rather than a superior choice.

    Medtronic's surgical robot is a key growth bet, and the mixed signals on how well it can challenge Intuitive matter for future sales.

June 2026
▲2

Medtronic gains on rival stumbles, acquisitions, and AI push

  • Competitor weakness in electrophysiology Boston Scientific's 2026 guidance missed expectations, with its electrophysiology growth slowing. Analysts say Medtronic may be taking market share in that heart-rhythm device business, which would lift Medtronic's sales and support its stock price.

    Shows a real competitive win that can boost Medtronic's revenue and investor sentiment.

  • Completes $550 million Scientia Vascular acquisition Medtronic finished buying Scientia Vascular for $550 million, adding specialized guidewires and catheters for brain blood vessels. The deal slightly lowers earnings per share in fiscal 2027 but is expected to add to earnings after that, strengthening its neurovascular business.

    A concrete capital move that expands a key product line and has a clear, if delayed, financial benefit.

  • Tariff hit lowered but still a growing cost Medtronic's CEO cut the expected tariff cost for fiscal 2027 to $250 million from $300 million, thanks to supply-chain changes. But tariffs remain a real and rising expense, and new U.S. tariff threats could force another rethink. Strong growth in heart ablation and other units helps offset the pressure.

    Tariffs directly affect Medtronic's costs and profits, and the lowered estimate is a fresh update investors need to weigh.

  • Robotic surgery competition cuts both ways Jim Cramer warned that Intuitive Surgical now faces real competition from Medtronic's Hugo robot, which is positive for Medtronic. But a separate report says Intuitive's dominant position is getting stronger, with most surgeons trained on its system and hospitals reluctant to switch, making Hugo an alternative rather than a superior choice.

    Medtronic's surgical robot is a key growth bet, and the mixed signals on how well it can challenge Intuitive matter for future sales.

▲2

Medtronic gains on rival stumbles, acquisitions, and AI push

  • Competitor weakness in electrophysiology Boston Scientific's 2026 guidance missed expectations, with its electrophysiology growth slowing. Analysts say Medtronic may be taking market share in that heart-rhythm device business, which would lift Medtronic's sales and support its stock price.

    Shows a real competitive win that can boost Medtronic's revenue and investor sentiment.

  • Completes $550 million Scientia Vascular acquisition Medtronic finished buying Scientia Vascular for $550 million, adding specialized guidewires and catheters for brain blood vessels. The deal slightly lowers earnings per share in fiscal 2027 but is expected to add to earnings after that, strengthening its neurovascular business.

    A concrete capital move that expands a key product line and has a clear, if delayed, financial benefit.

  • Tariff hit lowered but still a growing cost Medtronic's CEO cut the expected tariff cost for fiscal 2027 to $250 million from $300 million, thanks to supply-chain changes. But tariffs remain a real and rising expense, and new U.S. tariff threats could force another rethink. Strong growth in heart ablation and other units helps offset the pressure.

    Tariffs directly affect Medtronic's costs and profits, and the lowered estimate is a fresh update investors need to weigh.

  • Robotic surgery competition cuts both ways Jim Cramer warned that Intuitive Surgical now faces real competition from Medtronic's Hugo robot, which is positive for Medtronic. But a separate report says Intuitive's dominant position is getting stronger, with most surgeons trained on its system and hospitals reluctant to switch, making Hugo an alternative rather than a superior choice.

    Medtronic's surgical robot is a key growth bet, and the mixed signals on how well it can challenge Intuitive matter for future sales.